Molecular-level effects of eribulin and paclitaxel on breast cancer based on differential co-expression network analysis
We investigated the effects of eribulin and paclitaxel on breast cancer (BC) by exploring molecular biomarkers and pathways. Co-expression networks were constructed by differentially co-expressed genes and links, and centralities were analyzed to explore the hub genes. Pathway-enrichment analysis was performed. The hub genes were validated using the polymerase chain reaction and western blotting. A total of 132 and 153 differentially expressed genes were identified in BC cell lines treated with eribulin and paclitaxel, respectively.